He, Yingxia
Wang, Jie
Yao, Fang
Lu, Pan
Xie, Yafang
Li, Xiuwen
Liu, Qiangwei
Liu, Yang
Cao, Dan
Liang, Jun
Tian, Dan
Liu, Guan
Article History
Accepted: 29 May 2024
First Online: 23 July 2024
Declarations
:
: This study was funded by Hubei Duorui Pharmaceutical Company.
: All authors declare no conflicts of interest in this study.
: All the protocol and documents were reviewed and approved by the Ethics Committee of Wuhan Pulmonary Hospital (NO.2021004).
: All study participants provided written informed consent.
: All researchers, participants, institutions, and sponsors consented to the submission of this report to the journal.
: The principal investigator for this study was Guan Liu. Patient recruitment and data collection were undertaken by Fang Yao and Pan Lu. Vital signs monitoring was performed by Yafang Xie, Xiuwen Li, Qiangwei Liu, and Yang Liu. Statistical analysis was conducted by Dan Cao and Jun Liang. The manuscript was written with contributions from Yingxia He, Jie Wang, and Dan Tian.
: Datasets used in the current analysis are available from Yingxia He on reasonable request.